Compare PKST & IRWD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PKST | IRWD |
|---|---|---|
| Founded | 2008 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 780.2M | 663.6M |
| IPO Year | 2014 | 2009 |
| Metric | PKST | IRWD |
|---|---|---|
| Price | $20.99 | $3.63 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 2 | 3 |
| Target Price | ★ $21.00 | $7.67 |
| AVG Volume (30 Days) | 491.8K | ★ 2.2M |
| Earning Date | 05-07-2026 | 05-11-2026 |
| Dividend Yield | ★ 1.91% | N/A |
| EPS Growth | N/A | ★ 1400.00 |
| EPS | N/A | ★ 0.24 |
| Revenue | $105,981,000.00 | ★ $298,276,000.00 |
| Revenue This Year | $12.08 | $57.95 |
| Revenue Next Year | $10.03 | $4.39 |
| P/E Ratio | ★ N/A | $13.96 |
| Revenue Growth | N/A | ★ 8.88 |
| 52 Week Low | $11.50 | $0.61 |
| 52 Week High | $21.00 | $5.78 |
| Indicator | PKST | IRWD |
|---|---|---|
| Relative Strength Index (RSI) | 78.34 | 52.72 |
| Support Level | $20.72 | $3.07 |
| Resistance Level | N/A | $3.95 |
| Average True Range (ATR) | 0.02 | 0.21 |
| MACD | -0.02 | 0.00 |
| Stochastic Oscillator | 85.71 | 66.09 |
Peakstone Realty Trust is an internally managed, publicly registered real estate investment trust (REIT) that owns and operates predominately single-tenant industrial and office properties with creditworthy tenants and long-term leases. Peakstone's portfolio consists of newer vintage, and well-located real estate assets in majorly high-growth coastal and sunbelt markets. The Industrial segment consists of industrial outdoor storage properties which have a low building-to-land ratio, or low coverage, maximizing yard space for the display, movement, and storage of materials and equipment.
Ironwood Pharmaceuticals Inc is a biotechnology company developing and commercializing life-changing therapies for people living with gastrointestinal, or GI, and rare diseases. It is focused on the development and commercialization of inventive product opportunities in areas of unmet need, leveraging its demonstrated expertise and capabilities in GI and rare diseases. LINZESS is its commercial product. LINZESS is also available for the treatment of adults with IBS-C or CIC in Mexico, adults with IBS-C or chronic constipation in Japan, and adults with IBS-C in China. Linaclotide is available under the trademarked name CONSTELLA for the treatment of adults with IBS-C or CIC and pediatric patients ages 6-17 years old with FC in Canada, and to adults with IBS-C in certain European countries.